WO2000066587A3 - Polyamines and their use in therapy - Google Patents

Polyamines and their use in therapy Download PDF

Info

Publication number
WO2000066587A3
WO2000066587A3 PCT/US2000/011591 US0011591W WO0066587A3 WO 2000066587 A3 WO2000066587 A3 WO 2000066587A3 US 0011591 W US0011591 W US 0011591W WO 0066587 A3 WO0066587 A3 WO 0066587A3
Authority
WO
WIPO (PCT)
Prior art keywords
novel
analogs
polyamine
polyamine analogs
polyamines
Prior art date
Application number
PCT/US2000/011591
Other languages
French (fr)
Other versions
WO2000066587A2 (en
Inventor
Benjamin Frydman
Laurence J Marton
Venodhar K Reddy
Aldonia Valasinas
Andrei V Blokhin
Hirak S Basu
Original Assignee
Slil Biomedical Corp
Benjamin Frydman
Laurence J Marton
Venodhar K Reddy
Aldonia Valasinas
Andrei V Blokhin
Hirak S Basu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2000615617A priority Critical patent/JP4743673B2/en
Application filed by Slil Biomedical Corp, Benjamin Frydman, Laurence J Marton, Venodhar K Reddy, Aldonia Valasinas, Andrei V Blokhin, Hirak S Basu filed Critical Slil Biomedical Corp
Priority to EP00928583A priority patent/EP1177197B1/en
Priority to AU46799/00A priority patent/AU4679900A/en
Priority to NZ515140A priority patent/NZ515140A/en
Priority to MXPA01011000A priority patent/MXPA01011000A/en
Priority to CA2371625A priority patent/CA2371625C/en
Priority to DE60029944T priority patent/DE60029944T2/en
Priority to BR0010701-8A priority patent/BR0010701A/en
Priority to IL14612700A priority patent/IL146127A0/en
Publication of WO2000066587A2 publication Critical patent/WO2000066587A2/en
Publication of WO2000066587A3 publication Critical patent/WO2000066587A3/en
Priority to IL146127A priority patent/IL146127A/en
Priority to HK02102572.0A priority patent/HK1040993B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/09—Diamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/16—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings
    • C07C211/18—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings containing at least two amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/20—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C07C211/22—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton containing at least two amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/20—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C07C211/23—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton the carbon skeleton containing carbon-to-carbon triple bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/36—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing at least two amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/14—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/70—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Abstract

Novel conformationally restricted polyamine analogs are provided, as well as compositions comprising these novel polyamine analogs. Methods of using the novel polyamine analogs in treatment of diseases such as cancer are also provided. Also provided is a method of delivering these analogs specifically to tumor cells by covalently attaching polyamine analogs to porphyrin compounds, along with novel polyamine-porphyrin covalent conjugates.
PCT/US2000/011591 1999-04-30 2000-04-27 Polyamines and their use in therapy WO2000066587A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA2371625A CA2371625C (en) 1999-04-30 2000-04-27 Polyamines and their use in therapy
EP00928583A EP1177197B1 (en) 1999-04-30 2000-04-27 Polyamines and their use in therapy
AU46799/00A AU4679900A (en) 1999-04-30 2000-04-27 Conformationally restricted polyamine analogs as disease therapies
NZ515140A NZ515140A (en) 1999-04-30 2000-04-27 Conformationally restricted polyamine analogs as disease therapies for cancer, epilepsy, alzheimers, infections, grafts and others
MXPA01011000A MXPA01011000A (en) 1999-04-30 2000-04-27 Conformationally restricted polyamine analogs as disease therapies.
JP2000615617A JP4743673B2 (en) 1999-04-30 2000-04-27 Polyamines and their use in therapy
DE60029944T DE60029944T2 (en) 1999-04-30 2000-04-27 POLYAMINE AND ITS THERAPEUTIC USE
BR0010701-8A BR0010701A (en) 1999-04-30 2000-04-27 Conformationally restricted polyamine analogs as disease therapies
IL14612700A IL146127A0 (en) 1999-04-30 2000-04-27 Conformationally restricted polymine analogs as disease therapies
IL146127A IL146127A (en) 1999-04-30 2001-10-23 Conformationally restricted polyamine analogs and uses thereof
HK02102572.0A HK1040993B (en) 1999-04-30 2002-04-06 Polyamines and their use in therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13177999P 1999-04-30 1999-04-30
US60/131,779 1999-04-30

Publications (2)

Publication Number Publication Date
WO2000066587A2 WO2000066587A2 (en) 2000-11-09
WO2000066587A3 true WO2000066587A3 (en) 2001-01-25

Family

ID=22450998

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/011591 WO2000066587A2 (en) 1999-04-30 2000-04-27 Polyamines and their use in therapy

Country Status (14)

Country Link
US (3) US6794545B1 (en)
EP (2) EP1177197B1 (en)
JP (2) JP4743673B2 (en)
AT (1) ATE335719T1 (en)
AU (3) AU4679900A (en)
BR (1) BR0010701A (en)
CA (1) CA2371625C (en)
DE (1) DE60029944T2 (en)
ES (1) ES2269138T3 (en)
HK (1) HK1040993B (en)
IL (2) IL146127A0 (en)
MX (1) MXPA01011000A (en)
NZ (1) NZ515140A (en)
WO (1) WO2000066587A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6809176B2 (en) 1999-04-30 2004-10-26 Slil Biomedical, Corporation Quinones as disease therapies

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ515140A (en) * 1999-04-30 2003-07-25 Slil Biomedical Corp Conformationally restricted polyamine analogs as disease therapies for cancer, epilepsy, alzheimers, infections, grafts and others
EP1173223A2 (en) * 1999-04-30 2002-01-23 Slil Biomedical Corporation Conjugates as therapies for cancers and prostate diseases
WO2001097794A2 (en) * 2000-06-21 2001-12-27 Georgetown University Inhibitors of matriptase for the treatment of cancer
US7045550B2 (en) 2001-08-07 2006-05-16 Wisconsin Alumni Research Foundation Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy
JP2005510524A (en) 2001-11-16 2005-04-21 アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド Treatment of neurodegenerative disorders by modulating the polyamine pathway
EP1448183A2 (en) * 2001-11-16 2004-08-25 ALS Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
CA2469354A1 (en) 2001-12-07 2003-06-19 Slil Biomedical Corporation Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor
AU2003210883A1 (en) 2002-02-07 2003-09-02 Wisconsin Alumni Research Foundation Polyamine compounds and compositions for use in conjunction with cancer therapy
MXPA04012841A (en) * 2002-06-26 2005-09-20 Cellgate Inc Porphyrin-polyamine conjugates for cancer therapy.
WO2005014524A2 (en) 2003-08-07 2005-02-17 Wisconsin Alumni Research Foundation Amino thiol compounds and compositions for use in conjunction with cancer therapy
JP2007537158A (en) * 2004-02-13 2007-12-20 メディクエスト セラピューティックス インク Polyamine analogues that activate antizyme frameshifts
FR2867189A1 (en) * 2004-03-08 2005-09-09 Ludovic Bourre New compound comprising protein kinase regulator and photoactivatable molecule, useful for treating protein kinase-related diseases, e.g. tumors and inflammation
WO2006041805A1 (en) * 2004-10-04 2006-04-20 Cellgate, Inc. Polyamine analogs as therapeutic agents for ocular diseases
JP2008519053A (en) * 2004-11-04 2008-06-05 アンディーノ，ラウル Synthesis of polyamine conjugates of small interfering RNA (siRNA) and conjugates formed thereby
US20090143456A1 (en) * 2005-02-11 2009-06-04 Marton Laurence J Polyamine Analogs as Modulators of Cell Migration and Cell Motility
CA2619005A1 (en) 2005-08-10 2007-02-22 Johns Hopkins University Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors
US20070232677A1 (en) * 2006-03-14 2007-10-04 Marton Laurence J Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds
WO2007111993A2 (en) * 2006-03-22 2007-10-04 Cellgate, Inc. Polyamine analogs as therapeutic agents for skin diseases
BR112012000862A8 (en) 2009-07-16 2018-01-09 Pathologica Llc oral pharmaceutical composition, low dose oral pharmaceutical composition for chronic administration, method of treating or delaying the onset or development of a condition, method of treating pain in an individual in need of this drug, method of treating a condition in an individual who need this medicine
WO2013134047A2 (en) 2012-03-07 2013-09-12 The Mclean Hospital Corporation Aminoquinoline derivatives and uses thereof
WO2014100342A1 (en) 2012-12-20 2014-06-26 W. R. Grace & Co.-Conn. Container sealant composition
BR112015016189A8 (en) 2013-01-08 2019-10-22 Pathologica Llc uses of methylglyoxal bis (guanylhydrazone) ("mgbg"), use of methylglyoxal bis (guanylhydrazone) ("mgbg") and an agent and pharmaceutical composition
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
PT3149025T (en) 2014-05-21 2019-08-01 Entrada Therapeutics Inc Cell penetrating peptides and methods of making and using thereof
WO2016033368A1 (en) 2014-08-27 2016-03-03 Ohio State Innovation Foundation Improved peptidyl calcineurin inhibitors
US11576946B2 (en) 2018-01-29 2023-02-14 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-NFAT interaction
AU2019213664B2 (en) * 2018-01-30 2023-03-16 Panbela Therapeutics, Inc. Methods for producing (6S,15S)-3,8,13,18-tetraazaicosane-6,15-diol
CA3092062A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1295826B (en) * 1959-04-22 1969-05-22 Geigy Ag J R Process for the production of oxidation-resistant polyamides
US4035174A (en) * 1975-10-09 1977-07-12 Merck & Co., Inc. Novel dibicyclo [3.1.1] and [2.2.1] heptyl and dibicyclo [3.1.1] and [2.2.1] heptenyl polyamines and methods for their preparation
US4092432A (en) * 1975-10-22 1978-05-30 Kemanord Ab Mixtures having antimicrobial or pesticidal effect
US4153567A (en) * 1977-11-10 1979-05-08 Milliken Research Corporation Additives for lubricants and fuels
US4590288A (en) * 1983-06-29 1986-05-20 Exxon Research And Engineering Co. Bi- or polymetallic coordination complex
US5021571A (en) * 1989-06-29 1991-06-04 Associated Universities, Inc. Cyclohexyl EDTA monoanhydride
JPH0532902A (en) * 1991-07-31 1993-02-09 Idemitsu Petrochem Co Ltd Thermoplastic resin composition
WO1995018091A1 (en) * 1993-12-27 1995-07-06 Ciba-Geigy Ag Unsaturate amino compounds for use as anticancer and antiprotozoic agent
JPH07277964A (en) * 1994-04-08 1995-10-24 Nippon Kayaku Co Ltd Antitumor agent
US5541230A (en) * 1993-11-05 1996-07-30 Us Health Therapeutic polyamines
WO1996022962A1 (en) * 1995-01-23 1996-08-01 The Trustees Of Columbia University In The City Of New York Butyryl-tyrosinyl spermine, analogs thereof and methods of preparing and using same
WO1997002027A1 (en) * 1995-07-05 1997-01-23 Teva Pharmaceutical Industries, Ltd. Polyamine derivatives of 1-aminoindan
WO1998017624A1 (en) * 1996-10-18 1998-04-30 Wisconsin Alumni Research Foundation Conformationally restricted polyamines and their use as antineoplastic agents
US5889061A (en) * 1997-10-15 1999-03-30 Wisconsin Alumni Research Foundation Conformationally restricted polyamines
US5962533A (en) * 1996-02-06 1999-10-05 University Of Florida Research Foundation, Inc. Hydroxy polyamines

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2440724A (en) * 1944-10-27 1948-05-04 Commercial Solvents Corp Nu-substituted, 2-butene-1, 4-diamines, and process for preparing
US3008993A (en) * 1957-02-14 1961-11-14 Monsanto Chemicals Alkenyl polyamines
US3397223A (en) * 1966-05-19 1968-08-13 Shell Oil Co Preparation of cyclopropane derivatives
US3773833A (en) * 1970-07-14 1973-11-20 Monsanto Co Unsaturated polyamines
US4443604A (en) * 1979-07-31 1984-04-17 Standard Oil Company (Indiana) 1,4,Bis-N,N'-dipolyalkylquinonyl aminopropyl piperazine
US4491651A (en) 1982-05-17 1985-01-01 Petrolite Corporation Antistats containing acrylonitrile copolymers and polyamines
US4537601A (en) 1982-05-17 1985-08-27 Petrolite Corporation Antistats containing acrylonitrile copolymers and polyamines
US4661509A (en) * 1982-09-28 1987-04-28 Gordon Arnold Z Methods for treating leukopenia
JPS60126291A (en) * 1983-03-14 1985-07-05 Koichi Shiyudo Porphyrin derivative
US4551550A (en) 1983-12-06 1985-11-05 Merrell Dow Pharmaceuticals Inc. N-2,3-Butadienyl-1,4-butanediamine derivatives
DE3401675A1 (en) 1984-01-19 1985-07-25 Bayer Ag, 5090 Leverkusen NEW POLYAMINE AND A METHOD FOR THEIR PRODUCTION
CA1315780C (en) * 1986-01-17 1993-04-06 Yozo Fukuda Porphyrin derivatives
JPH0720963B2 (en) * 1986-01-17 1995-03-08 浜理薬品工業株式会社 Porphyrin derivative
US4698446A (en) 1986-07-01 1987-10-06 The Bf Goodrich Company Synthesis of polyamines and mixture formed thereby, of diprimary polyalkylene polyamines with disubstituted N-adjacent terminal carbon atom(s)
US4784736A (en) 1986-07-07 1988-11-15 Bend Research, Inc. Functional, photochemically active, and chemically asymmetric membranes by interfacial polymerization of derivatized multifunctional prepolymers
US6184232B1 (en) * 1986-12-02 2001-02-06 University Of Florida Analogs of biologically active, naturally occurring polyamines, pharmaceutical compositions and methods of treatment
US5677351A (en) * 1986-12-02 1997-10-14 University Of Florida Research Foundation, Inc. Sterically hindered tetraamines and method for their production
US5342945A (en) 1986-12-02 1994-08-30 University Of Florida Research Foundation, Inc. Anti-neoplastic, anti-viral or anti-retroviral spermine derivatives
US5091576A (en) * 1986-12-02 1992-02-25 University Of Florida Anti-neoplastic, anti-viral or anti-retroviral spermine derivatives
US5654484A (en) * 1987-10-08 1997-08-05 Merrell Pharmaceuticals Inc. Polyamine derivatives as antineoplastic agents
US4868219A (en) * 1988-04-07 1989-09-19 Thornfeldt Carl R Treatment of skin diseases with aliphatic amines
JPH01246286A (en) * 1988-03-28 1989-10-02 Hamari Yakuhin Kogyo Kk Porphyrin derivative
US4935449A (en) 1988-08-04 1990-06-19 Merrell Dow Pharmaceuticals Inc. N-2,3-butadienyl tri- and tetraaminoalkane derivatives
DE3827940A1 (en) * 1988-08-13 1990-03-01 Schering Ag 13,17-PROPIONIC ACID AND PROPIONIC ACID DERIVATIVE SUBSTITUTED PORPHYRINE COMPLEX COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THEM
US5374658A (en) 1988-10-26 1994-12-20 Ortho Phamaceutical Corporation Use of oxidized polyamines, especially NN'-bis-(3-propionaldehyde)-1-4-diaminobutane (spermine dialdehye) in graft treatment
US5719193A (en) * 1989-05-23 1998-02-17 Merrell Pharmaceuticals, Inc. Method of potentiating cell-mediated immunity utilizing polyamine derivatives
US5283367A (en) * 1989-08-30 1994-02-01 Ciba-Geigy Corporation Substituted 1,4-diamino-2-butene stabilizers
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
JP3007391B2 (en) * 1990-08-13 2000-02-07 花王株式会社 New quaternary ammonium compounds
US5561136A (en) 1990-12-13 1996-10-01 Merrell Pharmaceuticals Inc. Method of treating cancer by conjunctive therapy with N,N'-bis[ethylamino)propyl]-1,7-heptanediamine and a cytotoxic agent
US5354782A (en) 1991-01-17 1994-10-11 Merrell Dow Pharmaceuticals Inc. Polyamine phenols as radioprotective agents
US5217964A (en) 1991-01-23 1993-06-08 Merrell Dow Pharmaceuticals Inc. Polyamine thiols as radioprotective agents
GB9111794D0 (en) * 1991-05-31 1991-07-24 Robins David J Antifungal compounds
JP2684473B2 (en) 1991-09-02 1997-12-03 富士写真フイルム株式会社 Continuous production method of microcapsules
US5242684A (en) * 1991-10-25 1993-09-07 Isp Investments Inc. Antimicrobial, low toxicity, non-irritating composition comprising a blend of bis-quaternary ammonium compounds coprecipitated with a copolymer of vinylpyrrolidone and an acrylamido or vinyl quaternary ammonium monomer
US6051611A (en) * 1991-11-08 2000-04-18 Alcon Laboratories, Inc. Polymeric quaternary ammonium compounds and their use as ophthalmic antimicrobias
US5512597A (en) * 1991-11-08 1996-04-30 Alcon Laboratories, Inc. Polymeric quaternary ammonium compounds and their use as ophthalmic antimicrobials
CA2094341A1 (en) 1992-04-28 1993-10-29 Carl W. Porter Methods for the use of spermidine/spermine n1-acetyltransferase as a prognostic indicator and/or tumor response marker
DE4232925A1 (en) 1992-09-28 1994-03-31 Diagnostikforschung Inst 3-, 8-substituted deuteroporphyrin derivatives, pharmaceutical compositions containing them and process for their preparation
US5274090A (en) * 1992-11-09 1993-12-28 The Board Of Trustees Of The Leland Stanford Junior University Tetraphenylporphyrin compounds and method
NZ267211A (en) 1993-05-26 1997-11-24 Merrell Dow Pharma N-alkylthio polyamine derivatives, preparation and pharmaceutical compositions thereof
US5451347A (en) * 1993-06-24 1995-09-19 Lumigen, Inc. Methods and compositions providing enhanced chemiluminescence from chemiluminescent compounds using dicationic surfactants
CA2126889C (en) 1993-09-02 2005-06-14 Paul R. Hart Method of breaking reverse emulsions in a crude oil desalting system
US5413719A (en) 1994-01-18 1995-05-09 Nalco Chemical Company Fluorescent tracer in a water treatment process
DE4413402A1 (en) * 1994-04-18 1995-10-19 Hoechst Ag Process for the preparation of intermediates for the synthesis of glucose-6-phosphatase inhibitors and new intermediates
US5516807A (en) 1994-10-25 1996-05-14 Warner-Lambert Company Method for treating vascular proliferative disorders following balloon angioplasty
ES2125671T3 (en) 1994-10-31 1999-03-01 Cytec Tech Corp COAGULATION AND DECOLORATION PROCEDURES OF RESIDUAL CURRENTS.
USH1633H (en) 1995-03-08 1997-02-04 The Lubrizol Corporation Deodorizing polysulfide materials
US5912341A (en) * 1995-03-14 1999-06-15 Hoffman/Barrett, L.L.C. Heteroatom-functionalized porphyrazines and multimetallic complexes and polymers derived therefrom
US5612478A (en) 1995-03-30 1997-03-18 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5677349A (en) 1995-04-27 1997-10-14 Gilad; Gad M. Agmatine for the treatment of neurotrauma and neurodegenerative diseases
US5606053A (en) 1995-05-02 1997-02-25 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5677350A (en) 1995-06-07 1997-10-14 Wisconsin Alumni Research Foundation Inhibition of cancer cell growth, proliferation, and metastasis using N,N'-dα,ω-diaminoalkanes
US5608061A (en) 1995-08-02 1997-03-04 Johnson Matthey Plc Process for preparing 1,4,8,11-tetraazacyclotetradecane
GB9516929D0 (en) 1995-08-18 1995-10-18 Ciba Geigy Ag Pigment compositions
US5869715A (en) 1995-09-27 1999-02-09 The Reagents Of The University Of California Polyfunctional cationic cytofectins
US5886051A (en) * 1995-11-08 1999-03-23 University Of Florida Research Foundation, Inc. Methods and compositions for the treatment of neurodegeneration
US6126964A (en) * 1996-01-04 2000-10-03 Mirus Corporation Process of making a compound by forming a polymer from a template drug
US5744453A (en) 1996-01-05 1998-04-28 Mintz; Clifford S. Polyamine conjugates for treatment of infection
NZ331248A (en) * 1996-02-07 2000-03-27 Buckman Labor Inc Synergistic antimicrobial compositions containing an ionene polymer and a salt of dodecylamine and methods of using the same
AU2193797A (en) 1996-03-01 1997-09-16 Chiron Corporation Delivery of therapeutic agents to the prostate
US6034129A (en) * 1996-06-24 2000-03-07 Geltex Pharmaceuticals, Inc. Ionic polymers as anti-infective agents
US5958397A (en) * 1996-07-22 1999-09-28 Schering-Plough Healthcare Products, Inc. Method and composition for protecting against jellyfish stings
US5906996A (en) * 1996-08-21 1999-05-25 Murphy; Michael A. Tetramine treatment of neurological disorders
EP1459745A3 (en) * 1996-09-13 2004-12-15 University Of Florida Research Foundation, Inc. Method of inhibiting biosynthesis of elf5a
US5763388A (en) 1996-12-18 1998-06-09 Dsm Copolymer, Inc. Process for producing improved silica-reinforced masterbatch of polymers prepared in latex form
JPH10204040A (en) 1997-01-24 1998-08-04 Daicel Chem Ind Ltd Alicyclic polyamine and its production
US5843959A (en) 1997-03-19 1998-12-01 University Of Florida Research Foundation, Inc. Methods and bicyclic polyamine compositions for the treatment of inflammation
US6235794B1 (en) * 1997-04-03 2001-05-22 University Of Florida Biologically active spermidine analogues, pharmaceutical compositions and methods of treatment
US6307102B1 (en) * 1997-10-15 2001-10-23 Tosoh Corporation Amine catalyst for producing polyurethane and polyisocyanurate
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
WO1999054283A1 (en) 1998-04-21 1999-10-28 Universite Laval Polyamine transport inhibitors
WO1999062551A1 (en) * 1998-06-05 1999-12-09 Board Of Regents, The University Of Texas System Texaphyrin conjugates and uses thereof
DE19831217A1 (en) * 1998-07-03 2000-01-05 Schering Ag New porphyrin derivatives, pharmaceutical compositions containing them and their use in photodynamic therapy and MRI diagnostics
WO2000006136A2 (en) * 1998-07-31 2000-02-10 The Health Research, Inc. Therapeutic combination of polyamine with an anticancer agent
WO2000028998A1 (en) * 1998-11-16 2000-05-25 Rohto Pharmaceutical Co., Ltd. Liquid ophthalmic preparations
JP3747355B2 (en) * 1998-12-21 2006-02-22 独立行政法人理化学研究所 Chain polyamine compound and polyamine anticancer agent
US6649587B1 (en) 1999-04-30 2003-11-18 Slil Biomedical Corporation Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
EP1173223A2 (en) 1999-04-30 2002-01-23 Slil Biomedical Corporation Conjugates as therapies for cancers and prostate diseases
NZ515140A (en) * 1999-04-30 2003-07-25 Slil Biomedical Corp Conformationally restricted polyamine analogs as disease therapies for cancer, epilepsy, alzheimers, infections, grafts and others
US6673890B1 (en) * 1999-07-16 2004-01-06 Basf Aktiengesellschaft Zwitterionic polyamines and process for their production
GB9920107D0 (en) 1999-08-26 1999-10-27 Avecia Ltd Fluidising agents
FR2802817B1 (en) * 1999-12-23 2002-10-11 Centre Nat Rech Scient NOVEL GLYCOSIDASE INHIBITORS AND THEIR PHARMACOLOGICAL APPLICATIONS, PARTICULARLY FOR TREATING DIABETES
ATE361744T1 (en) * 2000-01-10 2007-06-15 Zetetic Res Inc USE OF A PHARMACEUTICAL COMPOSITION CONTAINING TWO QUATERNARY AMMONIUM COMPOUNDS AND ONE ORGANOMETAL COMPOUND FOR THE TREATMENT OF VIRAL AND FUNGAL INFECTIONS AND DISEASES
US7351807B2 (en) * 2000-01-18 2008-04-01 Mallinckrodt Inc. Cyanine-sulfenates for dual phototherapy
US6395257B1 (en) * 2000-01-18 2002-05-28 Mallinckrodt Inc. Dendrimer precursor dyes for imaging
US6444707B1 (en) * 2000-08-22 2002-09-03 West Agro Topically applied hoof treatment composition and concentrate
WO2002024185A2 (en) * 2000-09-19 2002-03-28 Dermal Therapy (Barbados) Inc. Topical analgesic compositions containing aliphatic polyamines and methods of using same
US6545181B1 (en) * 2000-10-24 2003-04-08 Pilot Chemical Holdings, Inc. Demulsifying compound and a method of breaking or inhibiting emulsions
WO2002043722A2 (en) * 2000-12-01 2002-06-06 The University Of British Columbia Copper chelators for treating ocular inflammation
US6399662B1 (en) * 2000-12-13 2002-06-04 University Of Florida Method and composition for the treatment of diarrhea and gastrointestinal spasms
US6635679B2 (en) * 2001-05-14 2003-10-21 Akzo Nobel N.V. Methods and compositions for inactivating viruses
WO2002096417A1 (en) * 2001-05-31 2002-12-05 Miravant Pharmaceuticals, Inc. Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and mri diagnosis
US6713653B2 (en) * 2001-08-24 2004-03-30 E. I. Du Pont De Nemours And Company Polyamines and polymers made therewith
IL161428A0 (en) * 2001-10-16 2004-09-27 Slil Biomedical Corp Oligoamine derivatives, methods for the production thereof and pharmaceutical compositions containing the same
US6458795B1 (en) 2001-11-15 2002-10-01 University Of Florida Method and composition for treatment of irritable bowel disease
JP2005510524A (en) * 2001-11-16 2005-04-21 アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド Treatment of neurodegenerative disorders by modulating the polyamine pathway
US6881732B2 (en) * 2002-06-13 2005-04-19 Chelator Llc Neuroprotection and cardioprotection afforded by chelators with high affinity and specificity for cations of first transition series elements
MXPA04012841A (en) * 2002-06-26 2005-09-20 Cellgate Inc Porphyrin-polyamine conjugates for cancer therapy.
US7189865B2 (en) * 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
US20040019043A1 (en) * 2002-07-23 2004-01-29 Dimitri Coucouvanis Thiomolybdate analogues and uses thereof
US20040192665A1 (en) * 2002-08-02 2004-09-30 Slil Biomedical Corporation Conjugates of porphyrin compounds with chemotherapeutic agents

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1295826B (en) * 1959-04-22 1969-05-22 Geigy Ag J R Process for the production of oxidation-resistant polyamides
US4035174A (en) * 1975-10-09 1977-07-12 Merck & Co., Inc. Novel dibicyclo [3.1.1] and [2.2.1] heptyl and dibicyclo [3.1.1] and [2.2.1] heptenyl polyamines and methods for their preparation
US4092432A (en) * 1975-10-22 1978-05-30 Kemanord Ab Mixtures having antimicrobial or pesticidal effect
US4153567A (en) * 1977-11-10 1979-05-08 Milliken Research Corporation Additives for lubricants and fuels
US4590288A (en) * 1983-06-29 1986-05-20 Exxon Research And Engineering Co. Bi- or polymetallic coordination complex
US5021571A (en) * 1989-06-29 1991-06-04 Associated Universities, Inc. Cyclohexyl EDTA monoanhydride
JPH0532902A (en) * 1991-07-31 1993-02-09 Idemitsu Petrochem Co Ltd Thermoplastic resin composition
US5541230A (en) * 1993-11-05 1996-07-30 Us Health Therapeutic polyamines
WO1995018091A1 (en) * 1993-12-27 1995-07-06 Ciba-Geigy Ag Unsaturate amino compounds for use as anticancer and antiprotozoic agent
JPH07277964A (en) * 1994-04-08 1995-10-24 Nippon Kayaku Co Ltd Antitumor agent
WO1996022962A1 (en) * 1995-01-23 1996-08-01 The Trustees Of Columbia University In The City Of New York Butyryl-tyrosinyl spermine, analogs thereof and methods of preparing and using same
WO1997002027A1 (en) * 1995-07-05 1997-01-23 Teva Pharmaceutical Industries, Ltd. Polyamine derivatives of 1-aminoindan
US5962533A (en) * 1996-02-06 1999-10-05 University Of Florida Research Foundation, Inc. Hydroxy polyamines
WO1998017624A1 (en) * 1996-10-18 1998-04-30 Wisconsin Alumni Research Foundation Conformationally restricted polyamines and their use as antineoplastic agents
US5889061A (en) * 1997-10-15 1999-03-30 Wisconsin Alumni Research Foundation Conformationally restricted polyamines

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ALFONSO, IGNACIO ET AL: "Sequential biocatalytic resolution of (.+-.)-trans-cyclohexane-1,2- diamine. Chemoenzymic synthesis of an optically active polyamine", CHEM. COMMUN. (CAMBRIDGE), no. 21, 1996, pages 2471 - 2472, XP000952857 *
FISCHER, H. A.: "Synthesis of 3H-spermine", J. LABELLED COMPD., vol. 11, no. 1, 1975, pages 141 - 143, XP000956379 *
GOTO, MASAFUMI ET AL: "Stereochemical studies of metal chelates. III. Preparation and stereochemistry of cobalt(III) complexes with C-substituted triethylenetetramines at the central ethylenediamine bridge", INORG. CHEM., vol. 8, no. 2, 1969, pages 358 - 366, XP000952924 *
KOBIRO, KAZUYA ET AL: "Synthesis and molecular structures of nickel(II) alkyl-substituted cyclam complexes", INORG. CHEM., vol. 31, no. 4, 1992, pages 676 - 685, XP000957409 *
NAGARAJAN, SRINIVASAN ET AL: "Chemistry of naturally occurring polyamines. 11. Unsaturated spermidine and spermine derivatives", J. ORG. CHEM., vol. 52, no. 22, 1987, pages 5044 - 5046, XP000952844 *
PATENT ABSTRACTS OF JAPAN vol. 017, no. 327 (C - 1073) 22 June 1993 (1993-06-22) *
PATENT ABSTRACTS OF JAPAN vol. 1996, no. 02 29 February 1996 (1996-02-29) *
REDDY, VENODHAR K. ET AL: "Conformationally Restricted Analogs of 1N,12N-Bisethylspermine: Synthesis and Growth Inhibitory Effects on Human Tumor Cell Lines", J. MED. CHEM., vol. 41, no. 24, 1998, pages 4723 - 4732, XP000952845 *
SNYDER, RONALD D. ET AL: "Effects of polyamine analogs on the extent and fidelity of in vitro polypeptide synthesis", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 176, no. 3, 1991, pages 1383 - 1392, XP000952839 *
WUNZ, TIMOTHY P. ET AL: "New antitumor agents containing the anthracene nucleus", J. MED. CHEM., vol. 30, no. 8, 1987, pages 1313 - 1321, XP000867863 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6809176B2 (en) 1999-04-30 2004-10-26 Slil Biomedical, Corporation Quinones as disease therapies

Also Published As

Publication number Publication date
AU2004240213A1 (en) 2005-01-20
EP1698629A3 (en) 2006-11-29
DE60029944D1 (en) 2006-09-21
AU4679900A (en) 2000-11-17
US20040235962A1 (en) 2004-11-25
IL146127A0 (en) 2002-07-25
ES2269138T3 (en) 2007-04-01
JP4743673B2 (en) 2011-08-10
MXPA01011000A (en) 2003-06-30
JP2011084586A (en) 2011-04-28
AU2009200547A1 (en) 2009-03-05
ATE335719T1 (en) 2006-09-15
DE60029944T2 (en) 2007-04-05
JP2002543202A (en) 2002-12-17
US6794545B1 (en) 2004-09-21
CA2371625C (en) 2012-04-17
CA2371625A1 (en) 2000-11-09
NZ515140A (en) 2003-07-25
HK1040993B (en) 2006-11-10
EP1698629A2 (en) 2006-09-06
US7186825B2 (en) 2007-03-06
US20070161692A1 (en) 2007-07-12
WO2000066587A2 (en) 2000-11-09
IL146127A (en) 2011-11-30
EP1177197B1 (en) 2006-08-09
EP1177197A2 (en) 2002-02-06
HK1040993A1 (en) 2002-06-28
BR0010701A (en) 2002-02-13
AU2004240213B2 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
WO2000066587A3 (en) Polyamines and their use in therapy
ES2551233T3 (en) Methods for the preparation of cytotoxic conjugates of maitansinoids and agents that bind to cells
WO1997029779A3 (en) EGF-Genistein conjugates for the treatment of cancer
WO2002002563A3 (en) Substituted-triazolopyrimidines as anticancer agents
MEP4008A (en) Camptothecin derivatives having antitumor activity
WO2006020722A3 (en) Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
EP1933833B8 (en) Therapy for the treatment of overactive bladder
UA103758C2 (en) Insulin-oligomer conjugates, formulations and uses thereof
WO2001030381A3 (en) Use of csf-1 inhibitors
WO2004018000A3 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
IT1333697B (en)
BRPI0608175A2 (en) method of eliminating heterogeneous or mixed cell population in tumors as well as maytansinoid compounds
WO2003000928A3 (en) Methods for identification of cancer cell surface molecules and cancer specific promoters, and therapeutic uses thereof
YU44404A (en) Method for identification of tumor targeting enzymes
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
CA2468314A1 (en) The use of water-soluble lamarin in the treatment of cancer
WO2000057911A3 (en) Hapten-conjugated mammalian cells and methods of making and using thereof
WO2004112717A3 (en) Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof
WO2005027936A3 (en) Pharmaceutical compositions and therapeutical treatment with oligo-beta-(1, 3)-glucans
WO2000006136A3 (en) Therapeutic combination of polyamine with an anticancer agent
WO2001080888A3 (en) Method for treatment of tumors using photodynamic therapy
WO2004085387A3 (en) Water-soluble mono-pegylated tetrapyrrole derivatives for photodynamic therapy and method of production
WO2005041860A3 (en) Stem cells for use in locating and targeting tumor cells
EG22346A (en) Process for the preparation of conjugates useful in the treatment of prostate cancer
TW200504076A (en) 7-imino derivatives camptothecin having antitumor activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2371625

Country of ref document: CA

Ref country code: CA

Ref document number: 2371625

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/011000

Country of ref document: MX

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 615617

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 515140

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 46799/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000928583

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000928583

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2000928583

Country of ref document: EP